9.8.2026 | Forbes
In his latest Forbes article, WBB Securities President Dr Steve Brozak examines a fundamental challenge facing the U.S. healthcare system: how to appropriately value medical innovation.
Through the contrasting examples of Sovaldi, which transformed hepatitis C treatment, and Rasonque, a recently approved treatment for pancreatic cancer, Dr Brozak explores how pharmaceutical pricing and reimbursement can treat the economics of curative therapies differently from those of continuously administered medicines.
The article considers the implications for patients, insurers, biotechnology companies, and investors as increasingly sophisticated therapies create both extraordinary medical opportunities and significant affordability challenges. It also examines potential approaches—including outcomes-based agreements, multiyear payment models, and greater pricing transparency—that could better align the cost of treatment with the value delivered to patients.
Read the full article on Forbes:
https://www.forbes.com/sites/stephenbrozak/2026/09/08/what-price-healthcare-revmeds-rasonque-the-us-drug-pricing-paradox/
